Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · CIK 1676047 · FYE Jan 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.88Day −2.54%Mkt cap $35M1Y −61.8%Off 52W high −66.6%Vol (1Y) 62.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,850 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.3% of sh out |
| Days to cover11.4d |
| 13F net flow (QoQ)+0.35% |
| Top-10 13F concentration98.9% |
| Next report (est.)2026-09-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.8M |
| Earnings (TTM)-$8.1M |
| ROE−125.6% |
| Net margin−404.1% |
| Sales growth 3Y−0.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−36.6% |
| 1Y−61.8% |
| 3Y−26.2% |
| 5Y−62.7% |
| Since incept. (ann.)+8.6% |
Price return through 2026-07-29 · series begins 2017-11-30. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)62.3% |
| Ann. volatility (3Y)95.4% |
| Sharpe (1Y)−1.37 |
| Sharpe (3Y)0.30 |
| Max drawdown (1Y)−66.1% |
| Max drawdown (3Y)−73.1% |
| Beta (3Y vs SPY)2.39 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 174,927 | $617,492 | 1.44% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 70,053 | $247,329 | 0.58% | +16.9% |
| UBS Group AG | 32,664 | $115,304 | 0.27% | +2515.2% |
| VANGUARD FIDUCIARY TRUST CO | 25,111 | $88,642 | 0.21% | new |
| STATE STREET CORP | 24,966 | $88,130 | 0.21% | +0.0% |
| NORTHERN TRUST CORP | 13,945 | $49,226 | 0.11% | +0.0% |
| Haven Private, LLC | 11,366 | $40,122 | 0.09% | −0.5% |
| BlackRock, Inc. | 9,541 | $33,680 | 0.08% | +8.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-04-30 | 2026-06-11 | −$0.10 | — | $433,399 | −35.1% |
| 2026-01-31 | 2026-04-29 | — | — | $400,709 | −37.6% |
| 2025-10-31 | 2025-12-11 | −$0.32 | — | $346,058 | −46.4% |
| 2025-07-31 | 2025-09-09 | −$2.12 | — | $622,452 | +40.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-12 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
Pocono Pharmaceuticals 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
